High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.

BACKGROUND : Inherited mutations in the CDKN2A tumor suppressor gene, which encodes the p16(INK4a) protein, and in the cyclin-dependent kinase 4 (CDK4) gene confer susceptibility to cutaneous malignant melanoma. We analyzed families with two or more cases of melanoma for germline mutations in CDKN2A and CDK4 to elucidate the contribution of these gene defects to familial malignant melanoma and to the occurrence of other cancer types. METHODS : The entire CDKN2A coding region and exon 2 of the CDK4 gene of an affected member of each of 52 families from southern Sweden with at least two cases of melanoma in first- or second-degree relatives were screened for mutations by use of polymerase chain reaction-single-strand conformation polymorphism analysis. Statistical tests were two-sided. RESULTS : CDKN2A mutations were found in 10 (19%) of the 52 families. Nine families carried an identical alteration consisting of the insertion of arginine at position 113 of p16(INK4a), and one carried a missense mutation, in which the valine at position 115 was replaced with a glycine. The 113insArg mutant p16(INK4a) was unable to bind cdk4 and cdk6 in an in vitro binding assay. Six of the 113insArg families had at least one member with multiple primary melanomas; the 113insArg families also had a high frequency of other malignancies-in particular, breast cancer (a total of eight cases compared with the expected 2.1; P =.0014) and pancreatic cancer (a total of six cases compared with the expected 0.16; P<.0001). Families with breast cancer also had a propensity for multiple melanomas in females, suggesting that a sex-dependent factor may modify the phenotypic expression of CDKN2A alterations. CONCLUSIONS : Our findings confirm that the majority of CDKN2A-associated melanoma families in Sweden are due to a single founder mutation. They also show that families with the CDKN2A 113insArg mutation have an increased risk not only of multiple melanomas and pancreatic carcinoma but also of breast cancer.

[1]  H. Olsson,et al.  Familial breast and ovarian cancer: a Swedish population-based register study. , 2000, American journal of epidemiology.

[2]  A M Goldstein,et al.  Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. , 1995, The New England journal of medicine.

[3]  Rajiv Kumar,et al.  Selective deletion of exon 1β of the p19ARF gene in metastatic melanoma cell lines , 1998, Genes, chromosomes & cancer.

[4]  Kari Hemminki,et al.  Interaction of breast cancer and melanoma genotypes , 1997, The Lancet.

[5]  D. Duffy,et al.  CDKN2A variants in a population-based sample of Queensland families with melanoma. , 1999, Journal of the National Cancer Institute.

[6]  G. Bianchi‐Scarrǎ,et al.  Familial melanoma and pancreatic cancer. Ligurian Skin Tumor Study Group. , 1996, The New England journal of medicine.

[7]  B. Achinstein,et al.  Journal of the National Cancer Institute, Vol. 29, 1962: Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance. , 2009, Nutrition reviews.

[8]  P. Pollock,et al.  CDKN2A mutation in a non‐FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein , 1997, International journal of cancer.

[9]  J. Slingerland,et al.  Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. , 1995, Oncogene.

[10]  T. Wright,et al.  Typing of human papillomaviruses by polymerase chain reaction amplification with L1 consensus primers and RFLP analysis. , 1992, Molecular and cellular probes.

[11]  D. Carson,et al.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.

[12]  T. Möller,et al.  Increased cancer risk in offspring of women with colorectal carcinoma , 2000, Cancer.

[13]  F. Zindy,et al.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.

[14]  Å. Borg,et al.  Novel germline p16 mutation in familial malignant melanoma in southern Sweden. , 1996, Cancer research.

[15]  M. Skolnick,et al.  Genetic predisposition to melanoma. , 1994, European journal of cancer.

[16]  L. Sandkuijl,et al.  Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds , 1995, Nature Genetics.

[17]  N. Gruis,et al.  Familial melanoma and pancreatic cancer. , 1996, The New England journal of medicine.

[18]  N. Hayward,et al.  Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma , 1996, Nature Genetics.

[19]  B. Dynlacht,et al.  Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition , 1995, Nature.

[20]  G. Peters,et al.  The p16INK4a/CDKN2A tumor suppressor and its relatives. , 1998, Biochimica et biophysica acta.

[21]  K. Isselbacher,et al.  Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Skolnick,et al.  Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. , 1992, Science.

[23]  David Hogg,et al.  Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma , 1999, Nature Genetics.

[24]  B. Peters,et al.  Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. , 1995, Oncogene.

[25]  R. MacKie,et al.  CDKN2A germline mutations in U.K. patients with familial melanoma and multiple primary melanomas. , 1998, The Journal of investigative dermatology.

[26]  J. Cayuela,et al.  Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. , 1998, Cancer research.

[27]  H. Varmus,et al.  Mutations associated with familial melanoma impair p16INK4 function , 1995, Nature Genetics.

[28]  G. Peters,et al.  Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information , 1999, Oncogene.

[29]  L. Chin,et al.  Malignant melanoma: modern black plague and genetic black box. , 1998, Genes & development.

[30]  J. Bystryn,et al.  CDKN2A mutations in multiple primary melanomas. , 1998, The New England journal of medicine.

[31]  R. Sutherland,et al.  Cancer‐associated mis‐sense and deletion mutations impair p16INK4 CDK inhibitory activity , 1996, International journal of cancer.

[32]  H. Höfler,et al.  CDKN2a/p16INK4a mutations and lack of p19ARF involvement in familial melanoma kindreds. , 1998, The Journal of investigative dermatology.

[33]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[34]  M. Skolnick,et al.  Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus , 1994, Nature Genetics.

[35]  M. Inganäs,et al.  Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. , 1997, Journal of the National Cancer Institute.

[36]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[37]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[38]  A. Olshan,et al.  Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele. , 1996, Journal of the National Cancer Institute.

[39]  G. Peters,et al.  Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma , 1996, Molecular and cellular biology.

[40]  D. Bishop,et al.  Germline mutations of the CDKN2 gene in UK melanoma families. , 1997, Human molecular genetics.

[41]  P. Goodfellow,et al.  Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. , 1995, The New England journal of medicine.

[42]  N. Hayward,et al.  Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. , 1995, Human molecular genetics.

[43]  D. Stoppa-Lyonnet,et al.  Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. , 1998, Human molecular genetics.